Abstract:

Panobinostat is a potent pan-deacetylase inhibitor that affects the growth and survival of multiple myeloma (MM) cells through alteration of epigenetic mechanisms and protein metabolism. Panobinostat plus bortezomib and dexamethasone (PAN-BTZ-Dex) led to a significant increase in progression-free survival (PFS) vs placebo plus bortezomib and dexamethasone (Pbo-BTZ-Dex) in patients with relapsed or relapsed and refractoryMMin the phase 3PANORAMA1 trial. This subgroup analysis evaluated outcomes in patients in the PANORAMA 1 trial based on prior treatment: A prior immunomodulatory drug (IMiD; n 5 485), prior bortezomib plus an IMiD (n 5 193), and ≥2 prior regimens including bortezomib and an IMiD (n5147). Median PFS with PAN-BTZ-Dex vs Pbo-BTZ-Dex across subgroups was as follows: prior IMiD (12.3 vs 7.4 months; hazard ratio [HR], 0.54; 95% confidence interval [CI], 0.43-0.68), prior bortezomib plus IMiD (10.6 vs 5.8 months; HR, 0.52;95%CI, 0.36-0.76),and ≥2 prior regimens including bortezomib and an IMiD (12.5 vs 4.7 months; HR, 0.47; 95% CI, 0.31-0.72). Common grade 3/4 adverse events and laboratory abnormalities in patients who received PAN-BTZ-Dex across the prior treatment groups included thrombocytopenia, lymphopenia, neutropenia, diarrhea, and asthenia/ fatigue. Incidence of on-treatment deaths among patients who received prior bortezomib and an IMiD (regardless of number of prior regimens) was similar between treatment arms. This analysis demonstrated a clear PFS benefit of 7.8 months with PAN-BTZ-Dex among patients who received ‡2 prior regimens including bortezomib and an IMiD, a population with limited treatment options and poorer prognosis. This trial was registered at www.clinicaltrials.gov as #NCT01023308. © 2016 by The American Society of Hematology.

Notes:

Cited By :18Export Date: 18 February 2017References: Kumar, S.K., Rajkumar, S.V., Dispenzieri, A., Improved survival in multiple myeloma and the impact of novel therapies (2008) Blood, 111 (5), pp. 2516-2520;Kumar, S.K., Dispenzieri, A., Lacy, M.Q., Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients (2014) Leukemia, 28 (5), pp. 1122-1128; Kumar, S.K., Lee, J.H., Lahuerta, J.J., Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study (2012) Leukemia, 26 (1), pp. 149-157. , International Myeloma Working Group; Atadja, P., Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges (2009) Cancer Lett, 280 (2), pp. 233-241; Hideshima, T., Richardson, P.G., Anderson, K.C., Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma (2011) Mol Cancer Ther, 10 (11), pp. 2034-2042; San-Miguel, J.F., Hungria, V.T., Yoon, S.S., Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial (2014) Lancet Oncol, 15 (11), pp. 1195-1206; Blade, J., Samson, D., Reece, D., Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation (1998) Br J Haematol, 102 (5), pp. 1115-1123. , Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant; Richardson, P.G., Barlogie, B., Berenson, J., A phase 2 study of bortezomib in relapsed, refractory myeloma (2003) N Engl J Med, 348 (26), pp. 2609-2617; Zee, B., Cole, B., Li, T., Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma (1998) J Clin Oncol, 16 (8), pp. 2834-2839; San-Miguel, J.F., Richardson, P.G., Gunther, A., Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma (2013) J Clin Oncol, 31 (29), pp. 3696-3703; Richardson, P.G., Schlossman, R.L., Alsina, M., PANORAMA 2: Panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma (2013) Blood, 122 (14), pp. 2331-2337; Stewart, A.K., Rajkumar, S.V., Dimopoulos, M.A., Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma (2015) N Engl J Med, 372 (2), pp. 142-152. , ASPIRE Investigators; Siegel, D.S., Martin, T., Wang, M., A phase 2 study of single-agent carfilzomib (PX-171-003- A1) in patients with relapsed and refractory multiple myeloma (2012) Blood, 120 (14), pp. 2817-2825; San, M.J., Weisel, K., Moreau, P., Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial (2013) Lancet Oncol, 14 (11), pp. 1055-1066; Richardson, P.G., Siegel, D.S., Vij, R., Pomalidomide alone or in combination with lowdose dexamethasone in relapsed and refractory multiple myeloma: A randomized phase 2 study (2014) Blood, 123 (12), pp. 1826-1832; Acaster, S., Gaugris, S., Velikova, G., Yong, K., Lloyd, A.J., Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: A UK cross-sectional survey (2013) Support Care Cancer, 21 (2), pp. 599-607; Chanan-Khan, A.A., Giralt, S., Importance of achieving a complete response in multiple myeloma, and the impact of novel agents (2010) J Clin Oncol, 28 (15), pp. 2612-2624; Harousseau, J.L., Dimopoulos, M.A., Wang, M., Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma (2010) Haematologica, 95 (10), pp. 1738-1744; Giver, C.R., Jaye, D.L., Waller, E.K., Kaufman, J.L., Lonial, S., Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes (2011) Leukemia, 25 (2), pp. 362-365; Lonial, S., Waller, E.K., Richardson, P.G., SUMMIT/CREST Investigators. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma (2005) Blood, 106 (12), pp. 3777-3784

Website